Charmacy Pharmaceutical Co Ltd
HKEX:2289
Income Statement
Earnings Waterfall
Charmacy Pharmaceutical Co Ltd
Revenue
|
4.4B
CNY
|
Cost of Revenue
|
-4.1B
CNY
|
Gross Profit
|
283.4m
CNY
|
Operating Expenses
|
-176m
CNY
|
Operating Income
|
107.5m
CNY
|
Other Expenses
|
-56.1m
CNY
|
Net Income
|
51.3m
CNY
|
Income Statement
Charmacy Pharmaceutical Co Ltd
Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
3 397
N/A
|
3 540
+4%
|
3 670
+4%
|
3 796
+3%
|
4 096
+8%
|
4 214
+3%
|
3 935
-7%
|
3 621
-8%
|
3 493
-4%
|
3 645
+4%
|
3 992
+9%
|
4 124
+3%
|
3 794
-8%
|
3 688
-3%
|
4 175
+13%
|
4 557
+9%
|
4 404
-3%
|
|
Gross Profit | ||||||||||||||||||
Cost of Revenue |
(3 232)
|
(3 360)
|
(3 494)
|
(3 592)
|
(3 893)
|
(3 985)
|
(3 706)
|
(3 404)
|
(3 280)
|
(3 446)
|
(3 761)
|
(3 882)
|
(3 568)
|
(3 473)
|
(3 914)
|
(4 281)
|
(4 120)
|
|
Gross Profit |
165
N/A
|
180
+9%
|
176
-2%
|
204
+16%
|
203
-1%
|
229
+13%
|
229
+0%
|
217
-5%
|
213
-2%
|
199
-6%
|
230
+16%
|
242
+5%
|
225
-7%
|
215
-5%
|
262
+22%
|
276
+6%
|
283
+3%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(104)
|
(102)
|
(95)
|
(120)
|
(123)
|
(131)
|
(139)
|
(134)
|
(132)
|
(134)
|
(151)
|
(163)
|
(156)
|
(157)
|
(172)
|
(179)
|
(176)
|
|
Selling, General & Administrative |
(104)
|
(109)
|
(81)
|
(83)
|
(105)
|
(112)
|
(117)
|
(109)
|
(103)
|
(105)
|
(122)
|
(129)
|
(118)
|
(119)
|
(166)
|
(162)
|
(170)
|
|
Depreciation & Amortization |
0
|
0
|
(12)
|
(7)
|
(14)
|
(16)
|
(19)
|
(22)
|
(25)
|
(25)
|
(25)
|
(29)
|
(33)
|
(34)
|
(33)
|
(30)
|
0
|
|
Other Operating Expenses |
0
|
7
|
(3)
|
(30)
|
(3)
|
(4)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(5)
|
(4)
|
(4)
|
27
|
13
|
(5)
|
|
Operating Income |
61
N/A
|
78
+28%
|
81
+3%
|
84
+4%
|
80
-5%
|
97
+22%
|
90
-8%
|
83
-8%
|
81
-2%
|
65
-20%
|
79
+22%
|
79
-1%
|
70
-12%
|
58
-17%
|
90
+56%
|
97
+8%
|
107
+11%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
(19)
|
(21)
|
(8)
|
(11)
|
(24)
|
(27)
|
(28)
|
(26)
|
(27)
|
(27)
|
(28)
|
(33)
|
(38)
|
(35)
|
(31)
|
(32)
|
(37)
|
|
Non-Reccuring Items |
0
|
0
|
(0)
|
(2)
|
(0)
|
(5)
|
(2)
|
(2)
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
63
|
66
|
(4)
|
|
Total Other Income |
0
|
0
|
3
|
14
|
4
|
3
|
3
|
3
|
1
|
1
|
3
|
2
|
1
|
1
|
1
|
1
|
1
|
|
Pre-Tax Income |
42
N/A
|
57
+37%
|
76
+33%
|
85
+11%
|
60
-29%
|
67
+13%
|
64
-6%
|
57
-11%
|
55
-3%
|
39
-29%
|
55
+40%
|
48
-13%
|
33
-31%
|
24
-26%
|
122
+402%
|
131
+8%
|
67
-49%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
(15)
|
(19)
|
(20)
|
(22)
|
(16)
|
(20)
|
(19)
|
(15)
|
(15)
|
(10)
|
(14)
|
(12)
|
(10)
|
(6)
|
(32)
|
(35)
|
(16)
|
|
Income from Continuing Operations |
26
|
38
|
56
|
63
|
44
|
48
|
45
|
42
|
40
|
29
|
41
|
36
|
23
|
18
|
90
|
96
|
51
|
|
Income to Minority Interest |
0
|
0
|
0
|
(0)
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
26
N/A
|
38
+44%
|
56
+49%
|
63
+11%
|
45
-29%
|
48
+8%
|
45
-6%
|
42
-7%
|
40
-5%
|
29
-28%
|
41
+41%
|
36
-12%
|
23
-35%
|
18
-23%
|
90
+407%
|
96
+6%
|
51
-47%
|
|
EPS (Diluted) |
0.33
N/A
|
0.35
+6%
|
0.52
+49%
|
0.58
+12%
|
0.41
-29%
|
0.45
+10%
|
0.42
-7%
|
0.39
-7%
|
0.37
-5%
|
0.27
-27%
|
0.38
+41%
|
0.33
-13%
|
0.21
-36%
|
0.17
-19%
|
0.84
+394%
|
0.89
+6%
|
0.48
-46%
|